ABBOTINDIA
vs
BSE Sensex 30
Over the past 12 months, ABBOTINDIA has outperformed BSE Sensex 30, delivering a return of 13% compared to the BSE Sensex 30's 6% growth.
Stocks Performance
ABBOTINDIA vs BSE Sensex 30
Performance Gap
ABBOTINDIA vs BSE Sensex 30
Performance Gap
Performance By Year
ABBOTINDIA vs BSE Sensex 30
Abbott India Ltd
Glance View
Abbott India Ltd., a subsidiary of the global healthcare conglomerate Abbott Laboratories, operates as a key player in India’s pharmaceutical landscape. Nestled in the vibrant, ever-evolving Indian market, Abbott India has carved a niche for itself with a strategic focus on both innovation and localization. Its operations span the development, manufacture, and sale of a wide array of pharmaceutical products. By leveraging Abbott's global expertise and its deep understanding of local market dynamics, the company designs solutions catered to the unique health challenges faced by Indian consumers. Their product portfolio includes a diverse range of proprietary medicines, nutrition products, diagnostics, and branded generics, which address therapeutic areas like cardiology, women's health, gastroenterology, and metabolic disorders. Abbott India’s revenue engine primarily hinges on its extensive distribution networks and its substantial investments in research and development aimed at optimizing treatment paradigms. The company employs a customer-centric approach, working closely with healthcare professionals to ensure the accessibility of its medications across the country. By aligning its operations with the latest trends in healthcare needs and regulatory requirements, Abbott India ensures it remains at the forefront of serving its consumers efficiently. Its commitment to quality and continuous product improvement not only strengthens its market position but also fuels its growth trajectory in the Indian pharmaceutical sector, making it a formidable entity poised for sustained success in a dynamic industry.